1. Home
  2. RBKB vs CGEN Comparison

RBKB vs CGEN Comparison

Compare RBKB & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RBKB

Rhinebeck Bancorp Inc.

N/A

Current Price

$16.15

Market Cap

178.3M

Sector

Finance

ML Signal

N/A

Logo Compugen Ltd.

CGEN

Compugen Ltd.

HOLD

Current Price

$1.86

Market Cap

148.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RBKB
CGEN
Founded
1860
1993
Country
United States
Israel
Employees
168
N/A
Industry
Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
178.3M
148.7M
IPO Year
2018
2001

Fundamental Metrics

Financial Performance
Metric
RBKB
CGEN
Price
$16.15
$1.86
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$4.00
AVG Volume (30 Days)
17.7K
191.2K
Earning Date
04-27-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.70
N/A
Revenue
$3,002,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$164.92
P/E Ratio
$22.87
N/A
Revenue Growth
4.24
N/A
52 Week Low
$9.31
$1.13
52 Week High
$16.23
$2.38

Technical Indicators

Market Signals
Indicator
RBKB
CGEN
Relative Strength Index (RSI) 77.16 55.87
Support Level $11.38 $1.47
Resistance Level N/A $2.38
Average True Range (ATR) 0.62 0.09
MACD 0.14 0.01
Stochastic Oscillator 95.86 83.34

Price Performance

Historical Comparison
RBKB
CGEN

About RBKB Rhinebeck Bancorp Inc.

Rhinebeck Bancorp Inc is the holding company for Rhinebeck Bank which provides a full range of banking and financial services to consumer and commercial customers. Financial services, including investment advisory and financial product sales, are offered through a division of the Bank doing business as Rhinebeck Asset Management (RAM). The Bank's primary business activity is accepting deposits from the general public and using those funds to originate indirect automobile loans (automobile loans referred by automobile dealerships), commercial real estate loans (which include multi-family real estate loans and commercial construction loans), commercial business loans and one-to four-family residential real estate loans, and to purchase investment securities.

About CGEN Compugen Ltd.

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.

Share on Social Networks: